This is a routine corporate presentation update with no new material events. The raised revenue guidance and strong Q2 beat are positive but already disclosed in prior earnings. Monitor upcoming TILVANCE-301 interim analysis on ORR and IOV-LUN-202 registrational data for the next binary catalyst.
Price Chart
Executive Summary
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, highlighting strong Q2 2026 revenue of ~$99M (up ~66% YoY and >10% above guidance), raised full-year 2026 revenue guidance to $410M-$420M (midpoint up ~15% from prior $350M-$370M), and a cash position of ~$304M with runway into 2H 2028. The presentation also touts pipeline progress in NSCLC, sarcoma, and endometrial cancer, but this is a routine update of investor materials with no new material financial disclosures or binary catalysts.
Key Facts
- Q2 2026 revenue of ~$99M, >10% above guidance and ~66% YoY growth
- Full-year 2026 revenue guidance raised to $410M-$420M (midpoint $415M, up ~15% from prior $350M-$370M)
- Cash, cash equivalents, short-term investments, and restricted cash of ~$304M as of June 30, 2026, with runway into 2H 2028
- Gross margin from cost of sales of ~56% in Q2 2026 and 50% YTD
- ~100 authorized treatment centers in North America; >95% of addressable patients within 200 miles of an ATC
- TILVANCE-301 Phase 3 frontline melanoma trial enrollment on track; IOV-LUN-202 NSCLC trial shows 25.6% ORR with mDOR not reached at 25.4 months follow-up
- SARATOGA Phase 2 sarcoma registrational trial commenced in Q2 2026; IOV-END-201 endometrial cancer proof-of-concept cohorts enrollment complete
Financial Impact
Q2 2026 revenue ~$99M revenue; FY 2026 guidance raised to $410M-$420M; cash ~$304M cash; ~56% gross margin
Risk Factors
- Commercial adoption of Amtagvi may not sustain growth trajectory
- Clinical trial results may not support regulatory approvals in new indications
- Cash runway into 2H 2028 assumes no material changes in manufacturing, payor coverage, or revenue recognition
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-113763 |
| Document: tm2627047d1_8k.htm | 0001104659-26-113763 |
| Document: 0001104659-26-113763-index-headers.html | 0001104659-26-113763 |
| Document: 0001104659-26-113763-index.html | 0001104659-26-113763 |
| Document: 0001104659-26-113763.txt | 0001104659-26-113763 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $12.96 $12.92 | ▼ −0.31% | ▼ −0.07% | $14.56 (+12.35%) |
Oct 2, 2026 24d ago | 3 | $14.15 $12.96 | ▼ −8.41% | ▼ −8.96% | $14.56 (+2.90%) |
Sep 29, 2026 28d ago | 8-K | $14.45 $14.82 | ▲ +2.56% | ▲ +2.77% | $14.56 (+0.76%) |
Aug 21, 2026 9w ago | Press Release | $8.06 $8.44 | ▲ +4.71% | ▲ +4.39% | $14.56 (+80.65%) |
Aug 6, 2026 11w ago | 8-K | $6.34 $6.40 | ▲ +0.95% | ▲ +0.98% | $14.56 (+129.65%) |
Aug 6, 2026 11w ago | 8-K | $6.21 $6.34 | ▲ +2.09% | ▲ +1.48% | $14.56 (+134.46%) |
Jul 16, 2026 14w ago | Court Ruling | $5.00 $5.02 | ▼ −0.40% | ▼ −0.56% | $14.56 (−191.20%) |
Jul 2, 2026 16w ago | 8-K | $4.31 $4.19 | ▼ −2.78% | ▼ −3.66% | $14.56 (+237.82%) |
Jun 19, 2026 18w ago | Press Release | $4.06 $4.44 | ▲ +9.36% | ▲ +10.81% | $14.56 (+258.62%) |
Jun 18, 2026 18w ago | S-3ASR | $4.06 $4.44 | ▲ +9.36% | ▲ +10.81% | $14.56 (+258.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers